Renal Denervation Story Not Over Yet Despite SYMPLICITY HTN-3 Disappointment
This article was originally published in The Gray Sheet
Executive Summary
Even though the first major sham-controlled trial showed no benefit for renal denervation in treating hypertension, statements provided by companies developing the technology suggest they are not giving up on it yet.